| Budget Amount *help |
¥19,760,000 (Direct Cost: ¥15,200,000、Indirect Cost: ¥4,560,000)
Fiscal Year 2013: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2012: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2011: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
|
|---|
| Research Abstract |
We have newly developed a detection assay for IFN-lambda3 protein, being encoded by IL28B gene that predict the efficacy of pegylated interferon and ribavirin (Peg-IFN/RBV) therapy for chronic hepatitis C patients. Using this assay, we demonstrated that IFN-lambda3 levels in the supernatant of peripheral mononuclear cells stimulated with toll-like receptor 7 agonist or serum levels of IFN-lambda3 more favorably predict the efficay of Peg-IFN/RBV treatment rather than genetic variation of IL28B. We also demonstrated that human BDCA3+dendritic cells recognize hepatitis C virus and produce IFN-lambda3 through toll-like receptor 3 pathway.
|
